Stifel Nicolaus Lowers TransMedics Group (NASDAQ:TMDX) Price Target to $75.00

TransMedics Group (NASDAQ:TMDX) had its target price lowered by investment analysts at Stifel Nicolaus from $85.00 to $75.00 in a report issued on Tuesday,Benzinga reports. The firm presently has a “hold” rating on the stock. Stifel Nicolaus’ price target suggests a potential upside of 7.99% from the stock’s current price.

Other analysts also recently issued reports about the stock. Canaccord Genuity Group dropped their price objective on shares of TransMedics Group from $152.00 to $124.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. JPMorgan Chase & Co. lifted their price objective on shares of TransMedics Group from $114.00 to $149.00 and gave the stock a “neutral” rating in a report on Wednesday, February 25th. Wall Street Zen downgraded shares of TransMedics Group from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. UBS Group restated a “hold” rating on shares of TransMedics Group in a research report on Tuesday. Finally, Oppenheimer lowered shares of TransMedics Group from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 6th. Six analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. According to MarketBeat, TransMedics Group presently has a consensus rating of “Hold” and a consensus price target of $134.00.

TransMedics Group Price Performance

Shares of NASDAQ TMDX traded up $0.52 during mid-day trading on Tuesday, reaching $69.45. 579,213 shares of the company were exchanged, compared to its average volume of 1,078,747. TransMedics Group has a 52 week low of $60.10 and a 52 week high of $156.00. The company has a quick ratio of 6.19, a current ratio of 6.74 and a debt-to-equity ratio of 1.70. The stock has a market capitalization of $2.40 billion, a PE ratio of 15.78 and a beta of 2.07. The company’s 50 day moving average price is $97.13 and its 200 day moving average price is $120.17.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $0.30 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.32). TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.The company had revenue of $173.93 million for the quarter, compared to the consensus estimate of $174.44 million. During the same period in the prior year, the firm posted $0.70 earnings per share. The business’s revenue was up 21.2% on a year-over-year basis. Sell-side analysts forecast that TransMedics Group will post 1.98 earnings per share for the current fiscal year.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, Director Stephanie Lovell sold 1,193 shares of the company’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $149.62, for a total transaction of $178,496.66. Following the completion of the sale, the director directly owned 2,866 shares in the company, valued at $428,810.92. This represents a 29.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Anil P. Ranganath sold 864 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $139.12, for a total transaction of $120,199.68. Following the sale, the insider owned 13,091 shares of the company’s stock, valued at approximately $1,821,219.92. The trade was a 6.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 16,205 shares of company stock valued at $2,353,002. 6.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On TransMedics Group

Hedge funds and other institutional investors have recently modified their holdings of the company. Kensington Investment Counsel LLC bought a new position in shares of TransMedics Group during the third quarter valued at about $1,926,000. Fieldview Capital Management LLC bought a new position in shares of TransMedics Group during the third quarter valued at about $1,716,000. Citigroup Inc. raised its stake in shares of TransMedics Group by 29.3% during the third quarter. Citigroup Inc. now owns 76,785 shares of the company’s stock valued at $8,615,000 after acquiring an additional 17,414 shares during the last quarter. Fred Alger Management LLC raised its stake in shares of TransMedics Group by 303.8% during the third quarter. Fred Alger Management LLC now owns 150,741 shares of the company’s stock valued at $16,913,000 after acquiring an additional 113,408 shares during the last quarter. Finally, Lisanti Capital Growth LLC raised its stake in shares of TransMedics Group by 62.0% during the third quarter. Lisanti Capital Growth LLC now owns 56,901 shares of the company’s stock valued at $6,384,000 after acquiring an additional 21,771 shares during the last quarter. 99.67% of the stock is owned by institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post?transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.